Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pediatrix Medical (MD) Non Operating Investment Income (2022 - 2026)

Pediatrix Medical (MD) has disclosed Non Operating Investment Income for 4 consecutive years, with $164000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Investment Income rose 119.03% to $164000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 47.07% year-over-year, with the annual reading at $1.7 million for FY2025, 47.07% up from the prior year.
  • Non Operating Investment Income for Q4 2025 was $164000.0 at Pediatrix Medical, down from $309000.0 in the prior quarter.
  • The five-year high for Non Operating Investment Income was $1.7 million in Q3 2024, with the low at -$2.7 million in Q1 2022.
  • Average Non Operating Investment Income over 4 years is $129000.0, with a median of $200000.0 recorded in 2024.
  • Peak annual rise in Non Operating Investment Income hit 174400.0% in 2024, while the deepest fall reached 166.16% in 2024.
  • Over 4 years, Non Operating Investment Income stood at -$2.7 million in 2022, then skyrocketed by 148.84% to $1.3 million in 2023, then plummeted by 166.16% to -$862000.0 in 2024, then skyrocketed by 119.03% to $164000.0 in 2025.
  • According to Business Quant data, Non Operating Investment Income over the past three periods came in at $164000.0, $309000.0, and $429000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.